The Program for Drug Development in Leukemia (PDD-L) offers patients the most advanced treatments available for acute leukemia, myeloproliferative neoplasms, myelodysplastic syndromes, and chronic myeloid leukemia through participation in phase 1 clinical trials.  Within this program, we concentrate on trials with novel therapeutics and new mechanisms of action coupled with translational research that support future scientific discoveries.

In the PDD-L our goal is to:

• Improve the survival and quality of life of patients with leukemias and related diseases
• Rapidly translate preclinical science into novel treatments for patients
• Build an effective drug development program that excels in data collection, regulatory compliance, and rapid study activation. 

To make an appointment or refer a patient, please call 646-608-3749.

If you would like further information about the Program for Drug Development in Leukemia, please contact:

Eytan Stein, MD (Director)
steine@mskcc.org

PDDL Clinical Trial Team
PDDLResearch@mskcc.org